Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Synapse ; 73(9): e22116, 2019 09.
Article in English | MEDLINE | ID: mdl-31081950

ABSTRACT

Nicotine activates nicotinic acetylcholine receptors and improves cognitive and sensory function, in part by its actions in cortical regions. Physiological studies show that nicotine amplifies stimulus-evoked responses in sensory cortex, potentially contributing to enhancement of sensory processing. However, the role of specific cell types and circuits in the nicotinic modulation of sensory cortex remains unclear. Here, we performed whole-cell recordings from pyramidal (Pyr) neurons and inhibitory interneurons expressing parvalbumin (PV), somatostatin (SOM), and vasoactive intestinal peptide (VIP) in mouse auditory cortex, in vitro. Bath application of nicotine strongly depolarized and excited VIP neurons, weakly depolarized Pyr neurons, and had no effect on the membrane potential of SOM or PV neurons. The use of receptor antagonists showed that nicotine's effects on VIP and Pyr neurons were direct and indirect, respectively. Nicotine also enhanced the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) in Pyr, VIP, and SOM, but not PV, cells. Using Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), we show that chemogenetic inhibition of VIP neurons prevents nicotine's effects on Pyr neurons. Since VIP cells preferentially contact other inhibitory interneurons, we suggest that nicotine drives VIP cell firing to disinhibit Pyr cell somata, potentially making Pyr cells more responsive to auditory stimuli. In parallel, activation of VIP cells also directly inhibits Pyr neurons, likely altering integration of other synaptic inputs. These cellular and synaptic mechanisms likely contribute to nicotine's beneficial effects on cognitive and sensory function.


Subject(s)
Auditory Cortex/drug effects , Interneurons/drug effects , Nicotine/pharmacology , Pyramidal Cells/drug effects , Animals , Auditory Cortex/physiology , Female , Inhibitory Postsynaptic Potentials/drug effects , Interneurons/metabolism , Male , Mice , Nicotinic Agonists/pharmacology , Pyramidal Cells/physiology , Vasoactive Intestinal Peptide/metabolism
2.
Biol Psychol ; 116: 4-9, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26555718

ABSTRACT

This Special Issue focuses on the auditory-evoked mismatch negativity (MMN), an electrophysiological index of change, and its reduction in schizophrenia. The following brief review is an attempt to complement the behavioral and clinical contributions to the Special Issue by providing basic information on synaptic interactions and processing in auditory cortex. A key observation in previous studies is that the MMN involves activation of cortical N-methyl-D-aspartate (NMDA) receptors. Yet, NMDA receptor activation is regulated by a number of synaptic events, which also may contribute to the MMN reduction in schizophrenia. Accordingly, this review will focus on synaptic interactions, notably inhibitory regulation of NMDA receptor-mediated activity, in auditory cortex.


Subject(s)
Auditory Cortex/physiology , Electrical Synapses/physiology , Evoked Potentials, Auditory/physiology , Receptors, N-Methyl-D-Aspartate/metabolism , Animals , GABA Agents/metabolism , Humans , Interneurons/physiology , Mice , Rats , Receptors, GABA-B/metabolism , Receptors, Glutamate/metabolism , Schizophrenia/physiopathology
3.
Synapse ; 65(8): 804-13, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21218452

ABSTRACT

Connexin-36 (Cx36) gap junctions (GJs) appear to be involved in the synchronization of GABA interneurons in many brain areas. We have previously identified a population of Cx36-connected ventral tegmental area (VTA) GABA neurons that may regulate mesolimbic dopamine (DA) neurotransmission, a system implicated in reward from both natural behaviors and drugs of abuse. The aim of this study was to determine the effect mefloquine (MFQ) has on midbrain DA and GABA neuron inhibition, and the role Cx36 GJs play in regulating midbrain VTA DA neuron activity in mice. In brain slices from adolescent wild-type (WT) mice the Cx36-selective GJ blocker mefloquine (MFQ, 25 µM) increased VTA DA neuron sIPSC frequency sixfold, and mIPSC frequency threefold. However, in Cx36 KO mice, MFQ only increased sIPSC and mIPSC frequency threefold. The nonselective GJ blocker carbenoxolone (CBX, 100 µM) increased DA neuron sIPSC frequency twofold in WT mice, did not affect Cx36 KO mouse sIPSCs, and did not affect mIPSCs in WT or Cx36 KO mice. Interestingly, MFQ had no effect on VTA GABA neuron sIPSC frequency. We also examined MFQ effects on VTA DA neuron firing rate and current-evoked spiking in WT and Cx36 KO mice, and found that MFQ decreased WT DA neuron firing rate and current-evoked spiking, but did not alter these measures in Cx36 KO mice. Taken together these findings suggest that blocking Cx36 GJs increases VTA DA neuron inhibition, and that GJs play in key role in regulating inhibition of VTA DA neurons. Synapse, 2011. © 2011 Wiley-Liss, Inc.


Subject(s)
Antimalarials/pharmacology , Connexins/metabolism , Gap Junctions/metabolism , Mefloquine/pharmacology , Neurons/drug effects , Ventral Tegmental Area/drug effects , Animals , Dopamine/metabolism , Gap Junctions/drug effects , Gene Knock-In Techniques , Inhibitory Postsynaptic Potentials , Male , Mice , Mice, Knockout , Neurons/metabolism , Organ Culture Techniques , Patch-Clamp Techniques , Ventral Tegmental Area/metabolism , gamma-Aminobutyric Acid/metabolism , Gap Junction delta-2 Protein
4.
J Neurosci Res ; 88(10): 2207-16, 2010 Aug 01.
Article in English | MEDLINE | ID: mdl-20336775

ABSTRACT

Expanded polyglutamine tracts cause neurodegeneration through a toxic gain-of-function mechanism. Generation of inclusions is a common feature of polyglutamine diseases and other protein misfolding disorders. Inclusion formation is likely to be a defensive response of the cell to the presence of unfolded protein. Recently, the compound B2 has been shown to increase inclusion formation and decrease toxicity of polyglutamine-expanded huntingtin in cultured cells. We explored the effect of B2 on spinal and bulbar muscular atrophy (SBMA). SBMA is caused by expansion of polyglutamine in the androgen receptor (AR) and is characterized by the loss of motor neurons in the brainstem and spinal cord. We found that B2 increases the deposition of mutant AR into nuclear inclusions, without altering the ligand-induced aggregation, expression, or subcellular distribution of the mutant protein. The effect of B2 on inclusions was associated with a decrease in AR transactivation function. We show that B2 reduces mutant AR toxicity in cell and fly models of SBMA, further supporting the idea that accumulation of polyglutamine-expanded protein into inclusions is protective. Our findings suggest B2 as a novel approach to therapy for SBMA.


Subject(s)
Bulbo-Spinal Atrophy, X-Linked/drug therapy , Bulbo-Spinal Atrophy, X-Linked/metabolism , Neuroprotective Agents/pharmacology , Nitroquinolines/pharmacology , Peptides/metabolism , Piperazines/pharmacology , Receptors, Androgen/metabolism , Animals , Animals, Genetically Modified , Cell Line , Disease Models, Animal , Drosophila melanogaster , Humans , Intracellular Space/drug effects , Intracellular Space/metabolism , Intranuclear Inclusion Bodies/drug effects , Intranuclear Inclusion Bodies/metabolism , Ligands , Mutation , Protein Multimerization , Rats , Receptors, Androgen/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...